Salix Expands its Product Portfolio with US$300 M Oceana Therapeutics Buyout
By Heather Cartwright
Pharma Deals Review: Vol 2011 Issue 11 (Table of Contents)
Published: 29 Nov-2011
DOI: 10.3833/pdr.v2011.i11.1620 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Salix Pharmaceuticals has agreed to acquire privately held Oceana Therapeutics for US$300 M in cash in order to gain access to its two marketed therapies, Solesta® for faecal incontinence and Deflux® for vesicoureteral reflux...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS